Myriad Genetics (MYGN) Non-Current Deferred Tax Liability (2014 - 2023)

Myriad Genetics (MYGN) has reported Non-Current Deferred Tax Liability for 10 consecutive years, with $2.7 million the latest figure, recorded in Q3 2023.

• In Q3 2023, Non-Current Deferred Tax Liability fell 74.29% year-over-year to $2.7 million; the TTM figure through Sep 2023 stood at $2.7 million (down 74.29% YoY), while the FY2022 annual figure was $3.5 million, down 90.22% from the prior year.
• Non-Current Deferred Tax Liability eased to $2.7 million in Q3 2023 per MYGN's latest filing, from $3.7 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $174.3 million in Q4 2020 and bottomed at $2.7 million in Q3 2023.
• Historically, Non-Current Deferred Tax Liability has averaged $47.8 million across 5 years, with a median of $40.7 million in 2021.
• Annual changes were most pronounced in 2020 — Non-Current Deferred Tax Liability surged 130.86% — and 2022, when it tumbled 90.22%.
• Myriad Genetics' Non-Current Deferred Tax Liability stood at $75.5 million in 2019, then soared by 130.86% to $174.3 million in 2020, then slumped by 79.46% to $35.8 million in 2021, then sank by 90.22% to $3.5 million in 2022, then slipped by 22.86% to $2.7 million in 2023.
• Business Quant data shows MYGN's Non-Current Deferred Tax Liability at $2.7 million in Q3 2023, $3.7 million in Q2 2023, and $4.1 million in Q1 2023.